Drug Profile
Research programme: myocardial derived insulin-like growth factor 1 therapy - Gene Biotherapeutics
Alternative Names: Ad5IGF-1; Corgentin; mdIGF-1Latest Information Update: 14 Sep 2018
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Taxus Cardium Pharmaceuticals Group
- Class Gene therapies
- Mechanism of Action Insulin-like growth factor I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postmyocardial infarction
Most Recent Events
- 05 Sep 2018 Taxus Cardium Pharmaceuticals Group is now called Gene Biotherapeutics
- 25 Mar 2014 Discontinued - Preclinical for Postmyocardial infarction in USA (Intracoronary)
- 17 Mar 2014 Cardium Therapeutics is now called Taxus Cardium Pharmaceuticals Group Inc.